Monopar Therapeutics Inc. (MNPR) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-27
Business type: Asset play
How it makes money
Monopar generates no commercial revenue and relies entirely on equity financing and asset transactions to fund operations.
As a clinical-stage biopharmaceutical company, Monopar does not currently sell any approved products and has earned no commercial product revenues since inception. Its survival depends entirely on external financing, specifically through public and private stock offerings, at-the-market sales programs, and occasional asset transactions.
To eventually generate earnings, the company must successfully develop its product candidates—such as ALXN1840 for Wilson disease and its MNPR-101 radiopharmaceutical programs—gain regulatory approvals from agencies like the FDA, and establish commercial and distribution arrangements.
What protects it: the moat
Monopar relies on patents, regulatory designations, and orphan drug status to protect its pipeline candidates from future competition.
Management asserts that its competitive position relies on its scientific and clinical expertise to acquire and advance late-stage therapeutics. The company has secured Orphan Drug Designation for ALXN1840 in both the U.S. and the EU, alongside Fast Track designation from the FDA, which are intended to provide regulatory advantages and market exclusivity upon potential approval.
What growth costs
Monopar reinvests heavily in research, development, and clinical trials to advance its drug pipeline.
The company incurs substantial research and development expenses as well as general and administrative costs to execute its clinical programs. As of December 31, 2025, Monopar held $140.4 million in cash, cash equivalents, and investments, which management expects will fund operations at least through December 31, 2027, to file an NDA for ALXN1840 and advance its radiopharmaceutical trials.
What could damage it
If clinical trials fail or regulatory approval is denied, Monopar cannot commercialize its drugs and may be forced to cease operations entirely.
Because the company lacks commercial products and depends entirely on successful clinical development, any setbacks in trials for candidates like ALXN1840 or MNPR-101 would halt its path to commercialization. Without approval or additional funding, Monopar would be unable to generate revenue and could be forced to reduce or stop operations.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.